Navigation Links
Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
Date:11/1/2011

DEERFIELD, Ill., Nov. 1, 2011 /PRNewswire/ -- Takeda Global Research & Development Center, Inc., (Takeda) announced that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 25, 2012 for the review of its investigational type 2 diabetes therapy alogliptin, and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.  

Currently, the FDA is reviewing the new drug applications (NDA) for the investigational therapies, which were resubmitted on July 25, 2011; the FDA has categorized these as Class 2 responses, requiring up to six months for review. Alogliptin is a selective dipeptidyl peptidase IV inhibitor (DPP-4i) under investigation in the United States (U.S.) for the treatment of type 2 diabetes as an adjunct to diet and exercise. Discovered by Takeda San Diego, Inc., alogliptin is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), which play a role in regulating blood glucose levels. Pioglitazone was approved in 1999 for the treatment of type 2 diabetes as an adjunct to diet and exercise. If approved, alogliptin/pioglitazone will be the first type 2 diabetes treatment option in the U.S. to include both a DPP-4 inhibitor and a thiazolidinedione (TZD) in a single tablet.

According to the International Diabetes Federation, a staggering 285 million individuals were living with diabetes worldwide in 2010.

"As recent figures indicate that diabetes continues to be a serious global health challenge, Takeda remains deeply committed to researching new and important therapeutic options for patients living with type 2 diabetes," said David Recker, M.D., senior vice president, clinical science, Takeda Global Research & Development Center. "Phase 3 studies have demonstrated that the combination of a
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
2. Takeda Completes Acquisition and Names New CEO of Nycomed
3. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
4. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
5. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
6. Takeda to Acquire Nycomed
7. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
8. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
9. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
10. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
11. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... CITY, Calif. , Nov. 26, 2014  Genomic ... Kim Popovits , Chairman, Chief Executive Officer and ... Piper Jaffray Healthcare Conference at The New York Palace ... Wednesday, December 3 at 11:30 am Eastern Time (ET). ... webcast of the conference call, go to the  Investor ...
(Date:11/26/2014)... , November 26, 2014 Investor-Edge has ... VVUS ), Horizon Pharma PLC (NASDAQ: HZNP ... Johnson (NYSE: JNJ ), and Theravance Inc. (NASDAQ: ... can be accessed at: http://investor-edge.com/register . On ... up 0.07%, the Dow Jones Industrial Average edged 0.02% lower, ...
(Date:11/26/2014)... , Nov. 26, 2014  CARsgen, a leader in ... immunotherapy to treat a variety of cancers, today announced ... BVCF, a China -based healthcare private ... company focused on the development of new therapeutics for ... Shanghai Cancer Institute and Shanghai Renji Hospital, the company ...
Breaking Medicine Technology:Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2
... 25, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ... John H. Johnson as Chief Executive Officer, effective January 31, ... Savient,s board of directors. Mr. Johnson brings significant ... a Senior Vice President of Eli Lilly and Company and ...
... recently launched eCS Inpatient EHR V1.2 (eCS), the first ... medium hospitals. eCS,s uniqueness is the tight linkage of ... a single web-based software solution. The solution is offered ... simplified deployment. "eCS is an affordable solution ...
Cached Medicine Technology:Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 2Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 3Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 4eCareSoft Launches Comprehensive EHR for Small & Medium Hospitals 2
(Date:11/28/2014)... 28, 2014 Nipomo Family Dentistry ... Do, recently opened its doors at 195 N. Thompson ... with preventative care like teeth cleanings, oral exams, fillings, ... Invisalign, teeth whitening (and Kor whitening), laser whitening, gum ... Nipomo Family Dentistry’s five-person team also takes a philanthropic ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 ... is lowering prices and offering savings in abundance ... hair care, hair loss and cosmetic products such ... and Bosley, TheBeautyPlace.com offers competitive discounts on already ... sold at affordable prices giving customers savings year ...
(Date:11/27/2014)... 2014 Ericdress.com today announced a ... up to 85% off, on all its clothing, shoes and ... Dec. 1 – 7, 2014 only. , At the special ... Orders above $109 can enjoy an extra $10 discount. Moreover, ... The business specially recommended its new collection of 2015 evening ...
(Date:11/27/2014)... knows, Cyber Monday is a crazy shopping day. Owing to ... now providing many big promotions on its website. Customers can ... current prices. The discount are up to 80% off. So ... orders above $88) from Dec. 1 – 4 2014. , ... are willing to shop on the internet. As a leading ...
(Date:11/27/2014)... Recently, DressVe , the well-known trendy young women’s clothing ... valid during Nov. 29 – Dec. 3 2014. In the ... up to 90% off. In addition, free delivery is provided ... http://www.dressve.com/ , Dresses that combine trendy styles and ... somebody’s personality and figure. The designers of DressVe.com know this ...
Breaking Medicine News(10 mins):Health News:Nipomo Family Dentistry Opens New Dental Office in Nipomo 2Health News:Nipomo Family Dentistry Opens New Dental Office in Nipomo 3Health News:TheBeautyPlace.com Announces Double Savings 2Health News:Ericdress.com Special Monday Sales Are Ready For Everyone 2Health News:Tidebuy.com Launching Overcoats Sales for the Special Monday in 2014 2Health News:DressVe.com Introduces Its 2014 Special Monday Sales To The Global Customers 2
... TUESDAY, Jan. 25 (HealthDay News) -- It,s hard to help ... long-term is even tougher. But obese children whose parents took ... weight and kept it off for the next two years, ... study shows that targeting parents -- rather than the children ...
... a friendly bartender can be the source of more than ... suggests that some bartenders may be in a good position ... help connect them to the appropriate agency. Researchers at ... Foreign Wars posts in Ohio. The results showed that ...
... Colo. (Jan. 25, 2011) A new study led ... at The Children,s Hospital and Colorado Health Outcomes Program ... explores the barriers, facilitators and alternative approaches to providers ... immunization registry. Reminder or recall messages, usually in the ...
... by further developing a culture of safety in which all ... can work together to maximize safety, according to an invited ... (PRO), a new medical journal whose mission is to ... official journal of the American Society for Radiation Oncology (ASTRO). ...
... 25 (HealthDay News) -- Epilepsy was the likely cause of ... to a new study. Researchers reached the conclusion that ... descriptions of his hallucinations -- including his description of a ... life written by pupils and friends such as George Sand. ...
... cardiovascular surgery, resulting in elevated circulating levels of cell-free ... and gut wall integrity is unclear. A research ... the World Journal of Gastroenterology addresses this ... levels similar to those found during cardiovascular surgery. The ...
Cached Medicine News:Health News:Changing Parental Behavior May Help Obese Kids Lose Weight 2Health News:Changing Parental Behavior May Help Obese Kids Lose Weight 3Health News:Bartenders may have role in assisting troubled war veterans 2Health News:Bartenders may have role in assisting troubled war veterans 3Health News:New study finds reminders for immunizations challenging for pediatric practices 2Health News:New study finds reminders for immunizations challenging for pediatric practices 3Health News:Culture of safety key to reducing chances for medical errors 2
Transcranial vascular DWL doppler....
The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
Medicine Products: